As of today, September 29, 2023, the total number of shares and votes in XVIVO Perfusion AB (publ) is 31,499,470. The number of shares and votes has changed as a result of the directed new issue of 1,600,000 shares that the company announced on September 13, 2023.
Gothenburg, September 29, 2023
XVIVO Perfusion AB (publ)
For further information, please contact:
Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-09-29 06:15 CEST.